211
Participants
Start Date
January 31, 2013
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
Influenza A/H3N2 variant Vaccine
Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects \>/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
Emory Vaccine Center - The Hope Clinic, Decatur
University of Iowa - Infectious Disease Clinic, Iowa City
Baylor College of Medicine - Molecular Virology and Microbiology, Houston
Group Health Research Institute - Seattle, Seattle
National Institute of Allergy and Infectious Diseases (NIAID)
NIH